Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III study findings on cabozantinib vs placebo in patients with advanced hepatocellular carcinoma who have received prior treatment with sorafenib (Abstract 207).
Mark Saunders, MD, PhD, of Christie Hospital, discusses study findings on tumor sidedness and the influence of chemotherapy duration on disease-free survival (Abstract 558).
Pieter van der Sluis, MD, PhD, of the University Medical Center Utrecht, discusses study findings that compared robot-assisted minimally invasive thoracolaparoscopic esophagectomy vs open transthoracic esophagectomy for resectable esophageal cancer (Abstract 6).
David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the merits of preoperative chemotherapy vs chemoradiotherapy, the role of targeted agents, recent results from genomic profiling, and whether PET scans can guide neoadjuvant treatment.
Steven D. Leach, MD, of Dartmouth University’s Norris Cotton Cancer Center, discusses the personalized approach that GI cancers will require to make rational use of immunotherapy—including a subset of pancreatic cancers, which appear to be highly immunogenic and are associated with long-term survival.
Abraham J. Wu, MD, of Memorial Sloan Kettering Cancer Center, discusses his findings that suggest efforts to reduce lung dose, such as shrinking the treatment volumes or using proton therapy, may improve outcomes in esophageal cancer (Abstract 3).
